Table 3 Mixed-model meta-regression analysis of potential moderators of difference in brachial artery endothelium-dependent flow-mediated dilation.

From: Endothelial dysfunction in systemic lupus erythematosus – a case-control study and an updated meta-analysis and meta-regression

 

Regression coefficient (SE)

z-score

df

p-value

Age, year

0.004459(0.03261)

1.36791

24

0.172

Female,%

0.04538(2.70484)

0.01678

24

0.987

DM, %

−15.81709(7.98021)

−1.98204

19

0.047

HT, %

−0.46715(1.74889)

−0.26711

16

0.789

Smoking, %

0.59631(1.17388)

0.50798

15

0.611

Menopause, %

1.48237(1.01263)

1.46388

9

0.143

BMI, kg/m2

0.16425(0.15941)

1.03039

18

0.303

SBP, mmHg

−0.02230(0.02256)

−0.98834

16

0.323

DBP, mmHg

−0.04573(0.02272)

−2.01229

15

0.044

TC, mg/dL

−0.00495(0.00874)

−0.56697

20

0.571

HDL, mg/dL

0.01665(0.02836)

0.58723

18

0.557

LDL, mg/dL

0.00796(0.01714)

0.46419

16

0.643

TG, mg/dL

−0.00188(0.00909)

−0.20739

16

0.836

ESR, mm/hr

−0.08544(0.04023)

−2.12382

6

0.034

CRP, U/L

−0.00351(0.07112)

−0.04930

12

0.961

SLEDAI, unit

−0.07136(0.05891)

−1.21141

15

0.226

Renal involvement, %

−4.89258(2.21542)

−2.20843

10

0.027

Prednisolone use, %

−0.32784(1.26973)

−0.25820

17

0.796

Mean prednisolone dose, mg/day

−0.07484(0.06059)

−1.23531

12

0.217

HCQ use, %

−1.10975(1.48537)

−0.74712

17

0.455

Aspirin use, %

−2.17895(0.67208)

−3.24208

6

0.001

ACA positivity, %

−0.08995(2.4885)

−0.03688

12

0.971

APASx, %

−2.47656(3.01813)

−0.82056

4

0.412

Disease durations, months

0.00510(0.0382)

1.33454

16

0.182

  1. Abbreviations: SE, standard error; df, degree of freedom; DM, diabetes mellitus; HT, hypertension; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, total triglyceride; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; HCQ, hydroxychloroquine; ACA, anti-cardiolipin antibodies; APASx, antiphospholipid antibody syndrome.